Everolimus
- Generic Name
- Everolimus
- Brand Names
- Afinitor, Votubia, Zortress
- Drug Type
- Small Molecule
- Chemical Formula
- C53H83NO14
- CAS Number
- 159351-69-6
- Unique Ingredient Identifier
- 9HW64Q8G6G
- Background
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
- Indication
Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease.
Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib.
Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.
Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
- Associated Conditions
- Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors
- Associated Therapies
- -
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 27
- Registration Number
- NCT00934895
- Locations
- ๐บ๐ธ
Rutgers Cancer Institute of New Jersey (Hamilton), Hamilton, New Jersey, United States
๐บ๐ธCooper Hospital/University Medical Center, Camden, New Jersey, United States
๐บ๐ธRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2015-05-07
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 145
- Registration Number
- NCT00930930
- Locations
- ๐บ๐ธ
University of Alabama, Birmingham, Alabama, United States
๐บ๐ธHershey Medical Center, Hershey, Pennsylvania, United States
๐บ๐ธThe Methodist Hospital Research Institute, Houston, Texas, United States
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
- Conditions
- Recurrent Adult Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Marginal Zone LymphomaT-cell Adult Acute Lymphoblastic LeukemiaAdult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaNodal Marginal Zone B-cell LymphomaPost-transplant Lymphoproliferative DisorderRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Grade 3 Follicular Lymphoma
- Interventions
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 124
- Registration Number
- NCT00918333
- Locations
- ๐บ๐ธ
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
๐บ๐ธMark O Hatfield-Warren Grant Magnuson Clinical Center, Bethesda, Maryland, United States
๐บ๐ธMayo Clinic, Rochester, Minnesota, United States
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2014-12-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 113
- Registration Number
- NCT00915603
- Locations
- ๐บ๐ธ
Wilshire Oncology Medical Group, LaVerne, California, United States
๐บ๐ธMercy Hospital, Portland, Maine, United States
๐บ๐ธAventura Medical Center, Aventura, Florida, United States
Phase II Trial of EVEROLIMUS ยฑ Trastuzumab in Hormone-Refractory Metastatic Breast Cancer
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Emory University
- Target Recruit Count
- 70
- Registration Number
- NCT00912340
- Locations
- ๐บ๐ธ
Emory University Hospital Midtown, Atlanta, Georgia, United States
๐บ๐ธUniversity of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
๐บ๐ธEmory University Winship Cancer Institute, Atlanta, Georgia, United States
Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation
- First Posted Date
- 2009-05-18
- Last Posted Date
- 2009-05-18
- Lead Sponsor
- University Hospital, Antwerp
- Target Recruit Count
- 152
- Registration Number
- NCT00903188
- Locations
- ๐ง๐ช
Erasme University Hospital, Brussels, Belgium
๐ง๐ชUniversity Hospital, Ghent, Gent, Belgium
๐ง๐ชUniversity Hospital Brussels, Brussels, Belgium
Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma
- First Posted Date
- 2009-05-18
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 471
- Registration Number
- NCT00903175
- Locations
- ๐บ๐ธ
University of California at Los Angeles Dept. of UCLA (3), Los Angeles, California, United States
๐บ๐ธLoyola University Medical Center /Cardinal Bernardin Cancer Cardinal Bernardin Cancer (3), Maywood, Illinois, United States
๐บ๐ธBillings Clinic Dept of Billings Clinic(2), Billings, Montana, United States
Safety Study of Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation
- First Posted Date
- 2009-04-29
- Last Posted Date
- 2011-09-15
- Lead Sponsor
- Armin Goralczyk
- Target Recruit Count
- 29
- Registration Number
- NCT00890253
- Locations
- ๐ฉ๐ช
University Medical Center Goettingen, Goettingen, Germany
Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- First Posted Date
- 2009-04-23
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- GOG Foundation
- Target Recruit Count
- 150
- Registration Number
- NCT00886691
- Locations
- ๐บ๐ธ
Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States
๐บ๐ธCleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States
๐บ๐ธRiverside Methodist Hospital, Columbus, Ohio, United States
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
- Conditions
- Interventions
- First Posted Date
- 2009-04-10
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 656
- Registration Number
- NCT00879333
- Locations
- ๐ฌ๐ง
Novartis Investigative Site, Wolverhampton, United Kingdom
๐บ๐ธHenry Ford Hospital Dept. of Henry Ford Hospital, Detroit, Michigan, United States
๐บ๐ธUniversity of Washington Cancer Care Seattle Cancer Alliance, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.